Transaction Overview and Terms Mirum Pharmaceuticals Inc., a specialty pharmaceutical company focused on rare diseases, has reached an agreement to... Read more
Tag: #M&A
Viatris Exits Preferred Equity Stake in Biocon Biologics in Major Transaction
The global healthcare enterprise Viatris has executed definitive agreements for the divestiture of its entire convertible preferred equity holding in... Read more
Sandoz Finalizes Acquisition of Just-Evotec Biologics EU SAS, Reinforcing Biosimilars Leadership
(Basel, December 8, 2025) – Sandoz Group AG (SIX: SDZ/OTCQX: SDZNY), the global leader in affordable medicines, announced the successful... Read more
Pharma Megamerger: Major Drug Company Unifies $5.5 Billion Biologics Subsidiary
A major pharmaceutical company has announced the successful completion of a plan to fully integrate its Biologics subsidiary, officially making... Read more
Minimum Acceptance Threshold Met in Exchange Proposal Between Two Biotech Firms
(MAINZ, Germany, December 3, 2025) – The biotech firm BioNTech (Nasdaq: BNTX) recently announced that the minimum condition for its... Read more
Eli Lilly Secures Experimental Cancer Therapy from Scorpion in Up-to-$2.5 Billion Deal
Eli Lilly announced its plan to acquire an experimental cancer therapy from Scorpion Therapeutics for a total consideration of up... Read more
???? Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion to Boost Cardiovascular Pipeline
The Swiss pharmaceutical giant Novartis has reached an agreement to acquire Anthos Therapeutics, a biopharmaceutical firm majority-owned by the life... Read more
Merck Finalizes $3.4 Billion Acquisition, Enhancing Rare Tumor Portfolio
Merck has successfully completed its previously announced $3.4 billion acquisition of SpringWorks Therapeutics, a biopharmaceutical company based in Stamford, Connecticut.... Read more
Roche Commits $3.5 Billion to Bolster MASH Portfolio via 89bio Acquisition
Roche has announced its plan to acquire 89bio, a San Francisco-based biotechnology firm, in a strategic move valued at approximately... Read more









